Lowest Price Guaranteed From USD 4,799
The CRISPR gene editing therapies market is estimated to be worth $35 million in 2024 and is expected to grow at CAGR of 129% during the forecast period. Clustered regularly interspaced short palindromic repeats (CRISPR) are a family of DNA sequences, which constitute a primitive immune system that is responsible for protecting prokaryotic cells from phage infections. It was first described in 1987, however, its potential as a gene editing tool was not realized until 2012. Since then, the CRISPR revolution has not shown any signs of slowing down and has been responsible for significant advances in molecular biology and therapy development. Fundamentally, the CRISPR/Cas system involves specific palindromic DNA sequences which work in tandem with a family of caspase enzymes (Cas9, Cas12), in order to excise gene fragments with high precision. Compared to the other targeted nuclease-based systems, CRISPR is relatively faster, and cost-efficient; as a result, the demand for this gene editing tool is very high. The relatively recent discovery / development of novel accompanying nucleases, namely Cas12a, Cas13, Cas14 and dCas9, has significantly improved the precision of this technology. Presently, there are several companies using different variants of the CRISPR/Cas technology for basic research, and the development of gene editing solutions. However, the therapeutic use of this versatile genetic manipulation tool is only being investigated by a select few stakeholders in the pharmaceutical industry. The aforementioned scenario is attributed to the surrogate licensing model, which has granted exclusive control of the associated intellectual property (IP) to three leading players, namely Editas Medicine, CRISPR Therapeutics and Intellia Therapeutics, in the contemporary market.
Clinical trials of CRISPR gene editing therapies are currently focused mainly on oncological and hematological disorders; however, several CRISPR drug product candidates against certain neurological disorders and infectious diseases, specifically targeting recurrent conditions, are under investigation. Post 2014, the overall interest in CRISPR gene editing technology has grown exponentially, with several start-ups entering the market and 6 of the top 10 pharmaceutical companies restructuring their efforts in this direction. Over time, a substantial body of evidence has also been generated validating the therapeutic applications of CRISPR gene editing technology, which has, in turn, prompted the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and has caused investors to put in significant capital into innovator companies involved in CRISPR gene editing therapies market, over the last two years alone. In fact, the three leading companies in this industry segment together have combined market capitalization of more than USD 10 billion, and have raised more than USD 2.8 billion in various funding rounds. Despite the possibly limitless potential of the CRISPR/Cas technology, further investigation, probing its safety and therapeutic efficacy in large diverse populations, is required. Key impediments to approval and other existing challenges that are being addressed by stakeholders, include off-target toxicity-related concerns and complexities related to the delivery of CRISPR components into target cells. Concerning delivery, innovators in this field have reported notable success using different types of platforms for facilitating the intracellular administration of CRISPR components; examples of successful delivery methods include electroporation, AAV vectors and lipid nanoparticles (LNPs). A few companies are also evaluating bacteriophages as a potential delivery system for such products. Promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to push CRISPR drug pipeline to higher phases and on to commercialization. We believe that the CRISPR gene editing therapies market is likely to witness a commendable market growth during the forecast period.
Examples of key companies engaged in CRISPR gene editing therapies market (which have also been profiled in this market report; the complete list of companies is available in the full report) include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Excision BioTherapeutics, Locus Biosciences, Graphite Bio, Emendo Biotherapeutics (A Subsidiary of AnGes), Beam Therapeutics, Modalis Therapeutics and Refuge Biotechnologies. This gene editing therapies market report includes an easily searchable excel database of all the companies using Crispr Cas9 gene editing to develop therapeutics, worldwide.
Several recent developments have taken place in the field of CRISPR gene editing therapies market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “CRISPR Gene Editing Therapies Market, 2021-2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the CRISPR gene editing therapies market. The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in CRISPR gene editing therapies market, across different geographies.
Amongst other elements, the market research report includes:
The key objective of CRISPR gene editing therapies market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for CRISPR gene editing therapies market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the forecast period 2021-2030. For this purpose, we have segmented the future opportunity across [A] target therapeutic area (hematological disorders, oncological disorders, ophthalmic diseases, infectious diseases and others) [B] approach of therapy (ex vivo and in vivo), [C] type of therapy (CAR-T cell therapy, HSC therapy, T cell therapy, and TIL), [D] key geographical regions (North America, Europe and Asia-Pacific). To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.